Tuesday, 20 September 2022

European Commission approves Roches Vabysmo, antibody for the eye

European Commission approves Roches Vabysmo, antibody for the eye
European Commission approves Roches Vabysmo

Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME). These retinal conditions are two of the leading causes of vision loss worldwide, affecting more than 40 million people.

Pradip Mahajan Tue, 09/20/2022 - 14:39

source https://www.pharmatutor.org/pharma-news/2022/european-commission-approves-roches-vabysmo-antibody-for-the-eye

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...